Clinical trial
An Investigational Drug Study to Assess Weight Loss in Obese and Overweight…
NCT00384605 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00384605 |
|---|---|
| Title | An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED) |
| Official title | A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Obese Patients and in Overweight Patients With Obesity-Related Co-Morbidities, Followed by a 1-Year Extension |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | taranabant, placebo |
| Enrollment | 1,000 |
| Start date | Oct 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Oct 6, 2006 |
| Last update posted | Mar 13, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: